Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

Changes in gene expression also hint at how the brains of people with ASD develop differently from those of other people.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

Without knowing the cells’ mechanism of action, researchers question the best way to administer them to patients.

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.

Researchers use the technique to turn on Oct4 or Sox2 in mouse embryonic fibroblasts and convert them into pluripotent cells.